HK1099507A1 - Compositions for treating diabetes - Google Patents
Compositions for treating diabetesInfo
- Publication number
- HK1099507A1 HK1099507A1 HK07102258.6A HK07102258A HK1099507A1 HK 1099507 A1 HK1099507 A1 HK 1099507A1 HK 07102258 A HK07102258 A HK 07102258A HK 1099507 A1 HK1099507 A1 HK 1099507A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- treating diabetes
- diabetes
- treating
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53111903P | 2003-12-19 | 2003-12-19 | |
US59170904P | 2004-07-27 | 2004-07-27 | |
PCT/US2004/042884 WO2005063226A1 (fr) | 2003-12-19 | 2004-12-20 | Compositions et procedes pour le traitement du diabete |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1099507A1 true HK1099507A1 (en) | 2007-08-17 |
Family
ID=34742984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07102258.6A HK1099507A1 (en) | 2003-12-19 | 2007-02-28 | Compositions for treating diabetes |
Country Status (18)
Country | Link |
---|---|
US (2) | US7442720B2 (fr) |
EP (1) | EP1696897B1 (fr) |
JP (1) | JP4845740B2 (fr) |
KR (1) | KR101329369B1 (fr) |
CN (1) | CN101897970A (fr) |
AR (1) | AR047779A1 (fr) |
AT (1) | ATE515261T1 (fr) |
AU (1) | AU2004308934B2 (fr) |
BR (1) | BRPI0417829A (fr) |
CA (1) | CA2549717C (fr) |
HK (1) | HK1099507A1 (fr) |
IL (1) | IL176259A (fr) |
MX (1) | MXPA06007100A (fr) |
MY (1) | MY143799A (fr) |
RU (1) | RU2367423C2 (fr) |
SG (1) | SG149814A1 (fr) |
TW (1) | TWI350751B (fr) |
WO (1) | WO2005063226A1 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
CN100391448C (zh) * | 2003-11-19 | 2008-06-04 | 奥加生物药业(I.P.1)有限公司 | 提高乙醇代谢和减轻宿醉效应的物质和方法 |
EP1696897B1 (fr) * | 2003-12-19 | 2011-07-06 | Omega Bio-Pharma (I.P.3) Limited | Compositions pour le traitement du diabete |
US20050143473A1 (en) * | 2003-12-19 | 2005-06-30 | Wong Gary K.P. | Methods for treating allergy |
WO2005067899A2 (fr) * | 2004-01-13 | 2005-07-28 | Omega Bio-Pharma (I.P.2) Limited | Procede pour traiter le stress et agir sur des systemes immunitaires biologiques |
BRPI0510613A (pt) | 2004-05-03 | 2007-10-30 | Omega Bio Pharma Ip3 Ltd | cisteaminas para tratar complicações de hipercolesterolemia e diabete |
BRPI0512923A (pt) * | 2004-06-30 | 2008-04-15 | Omega Bio Pharma I P 1 Ltd | materiais e métodos para melhorar a saúde, imunidade e crescimento de mariscos |
US20070172514A1 (en) * | 2006-01-20 | 2007-07-26 | Francis Chi | Materials and methods for improving livestock productivity |
MX2008009647A (es) | 2006-01-27 | 2008-09-25 | Univ California | Cisteamina recubierta entéricamente, cistamina y derivados de ella. |
AU2013267044B2 (en) * | 2006-01-27 | 2016-07-07 | The Regents Of The University Of California | Enterically coated cysteamine, cystamine and derivatives thereof |
US8138227B2 (en) * | 2006-07-06 | 2012-03-20 | Trustees Of Dartmouth College | Method for inhibiting or reversing non-enzymatic glycation |
US7993687B2 (en) | 2006-07-12 | 2011-08-09 | Julianne Marie Kawa | Compositions and methods for management of diabetes |
ES2603879T3 (es) | 2007-07-19 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Preparación sólida que comprende alogliptina e hidrocloruro de metformina |
KR20100091219A (ko) | 2007-11-30 | 2010-08-18 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 시스테아민 산물을 이용한 비-알코올성 지방성간염(nash) 치료 방법 |
RU2657515C2 (ru) * | 2010-04-13 | 2018-06-14 | м-лаб ГмбХ | Способы диагностики глаукомы |
WO2011130719A2 (fr) | 2010-04-15 | 2011-10-20 | The Regents Of The University Of Michigan | Voie biosynthétique pour l'expression hétérologue d'un médicament de peptide synthétase non ribosomique et analogues |
GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
SI2661266T1 (sl) | 2011-01-07 | 2021-01-29 | Anji Pharma (Us) Llc | Terapije, na osnovi kemosenzoričnih receptorskih ligandov |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9480663B2 (en) * | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
AU2012213435B2 (en) * | 2011-02-02 | 2017-03-30 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
KR20140097132A (ko) * | 2011-11-22 | 2014-08-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 허혈성 손상을 치료하기 위한 시스테아민 및/또는 시스타민 |
MX2014008190A (es) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Composiciones de biguanida y métodos para tratar transtornos metabólicos. |
MX2014008189A (es) | 2012-01-06 | 2015-02-12 | Elcelyx Therapeutics Inc | Composiciones y metodos para tratar trastornos metabolicos. |
US20140314841A1 (en) | 2013-04-19 | 2014-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases |
TWI649100B (zh) | 2013-06-17 | 2019-02-01 | 地平線罕見醫學製藥有限責任公司 | 延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法 |
WO2015015403A2 (fr) * | 2013-08-01 | 2015-02-05 | Mahesh Kandula | Compositions et méthodes utilisables en vue du traitement du diabète et du pré-diabète |
EP3628640B1 (fr) * | 2014-09-02 | 2023-08-09 | Hub Therapeutics | Procédés de fabrication d'une molécule deutérée ou non-deutérée et formulations pharmaceutiques pour traitement |
GB201416716D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
RU2766579C2 (ru) | 2015-07-02 | 2022-03-15 | ХОРАЙЗОН ОРФАН ЭлЭлСи | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
AU2016326397A1 (en) * | 2015-09-22 | 2018-04-19 | Viking Therapeutics, Inc. | Conjoint therapies with inhibitors of glucose production |
WO2017062363A1 (fr) * | 2015-10-05 | 2017-04-13 | Joslin Diabetes Center | Procédés d'utilisation de bétatrophine |
CN106620715B (zh) * | 2015-11-04 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种治疗糖尿病的药物组合物及其制备方法 |
US10537528B2 (en) | 2015-11-16 | 2020-01-21 | The Regents Of The University Of California | Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds |
US10143665B2 (en) | 2015-11-17 | 2018-12-04 | Horizon Orphan Llc | Methods for storing cysteamine formulations and related methods of treatment |
US10155948B2 (en) | 2016-05-12 | 2018-12-18 | Kangwon National University University-Industry Cooperation Foundation and | Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications |
KR101881662B1 (ko) * | 2016-05-12 | 2018-07-26 | 강원대학교산학협력단 | 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법 |
US11357750B2 (en) | 2017-01-25 | 2022-06-14 | Children's Hospital Medical Center | Cysteamine prodrugs |
CN109439553B (zh) * | 2018-12-26 | 2020-08-21 | 华熙生物科技股份有限公司 | 产麦角硫因的菌株及其筛选方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062950A (en) * | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
DE3343141A1 (de) * | 1983-11-29 | 1985-06-05 | Hermann P.T. 7400 Tübingen Ammon | Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese |
CA1322526C (fr) | 1987-06-04 | 1993-09-28 | John I. Clark | Methode et reactifs chimiques pour la prevention ou l'inversion du processus de formation des cataractes par le recours a des inhibiteurs de la separation de phases |
US5401880A (en) | 1987-06-04 | 1995-03-28 | Oculon Corporation | Chemical prevention or reversal of cataract by phase separation inhibitors |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
CZ306394A3 (en) | 1993-12-14 | 1995-08-16 | Lilly Co Eli | Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof |
FR2716625B1 (fr) * | 1994-02-25 | 1996-04-26 | Gouchet Franck Arno | Préparation et utilisation de formes pharmaceutiques et cosmétiques contenant des composés d'inclusion avec les cyclodextrines de cystéamine, sels de cystéamine, ou dérivés de la cystéamine, sous forme de sel ou non. |
US5714519A (en) * | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
KR100245077B1 (ko) * | 1997-04-25 | 2000-02-15 | 김영환 | 반도체 메모리 소자의 딜레이 루프 럭크 회로 |
US6100736A (en) * | 1997-06-05 | 2000-08-08 | Cirrus Logic, Inc | Frequency doubler using digital delay lock loop |
FR2774591B1 (fr) | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
US6621496B1 (en) * | 1999-02-26 | 2003-09-16 | Micron Technology, Inc. | Dual mode DDR SDRAM/SGRAM |
US6521266B1 (en) | 1999-09-23 | 2003-02-18 | Morris A. Mann | Composition for growth hormone production and release, appetite suppression, and methods related thereto |
BR0015294A (pt) | 1999-11-03 | 2003-07-15 | Bristol Myers Squibb Co | Método para tratamento da diabetes |
US6630176B2 (en) | 2000-03-07 | 2003-10-07 | Mount Sinai School Of Medicine Of New York University | Herbal remedies for treating allergies and asthma |
WO2001082916A2 (fr) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Compositions therapeutiques combinees et leurs methodes d'utilisation |
WO2001095944A2 (fr) | 2000-06-12 | 2001-12-20 | Mills Randell L | Promedicaments destines a l'administration selective d'un medicament |
CN1144585C (zh) | 2000-12-13 | 2004-04-07 | 华扩达动物科学[I.P.2]有限公司 | 含有半胱胺或其盐类的促进动物快速生长的组合物及用途 |
JP3715529B2 (ja) | 2000-12-19 | 2005-11-09 | 雅嗣 田中 | アルコール代謝促進剤 |
US6746578B2 (en) * | 2001-05-31 | 2004-06-08 | International Business Machines Corporation | Selective shield/material flow mechanism |
JP2006508096A (ja) * | 2002-11-07 | 2006-03-09 | ディーエスエム アイピー アセッツ ビー.ブイ. | 没食子酸エピガロカテキンを含む新規な栄養補助組成物 |
US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
CN100391448C (zh) | 2003-11-19 | 2008-06-04 | 奥加生物药业(I.P.1)有限公司 | 提高乙醇代谢和减轻宿醉效应的物质和方法 |
US20050143473A1 (en) | 2003-12-19 | 2005-06-30 | Wong Gary K.P. | Methods for treating allergy |
EP1696897B1 (fr) * | 2003-12-19 | 2011-07-06 | Omega Bio-Pharma (I.P.3) Limited | Compositions pour le traitement du diabete |
BRPI0510613A (pt) * | 2004-05-03 | 2007-10-30 | Omega Bio Pharma Ip3 Ltd | cisteaminas para tratar complicações de hipercolesterolemia e diabete |
-
2004
- 2004-12-20 EP EP04815013A patent/EP1696897B1/fr not_active Not-in-force
- 2004-12-20 US US11/017,164 patent/US7442720B2/en not_active Expired - Fee Related
- 2004-12-20 JP JP2006545568A patent/JP4845740B2/ja not_active Expired - Fee Related
- 2004-12-20 SG SG200809465-8A patent/SG149814A1/en unknown
- 2004-12-20 MX MXPA06007100A patent/MXPA06007100A/es active IP Right Grant
- 2004-12-20 CA CA2549717A patent/CA2549717C/fr not_active Expired - Fee Related
- 2004-12-20 TW TW093139597A patent/TWI350751B/zh not_active IP Right Cessation
- 2004-12-20 BR BRPI0417829-7A patent/BRPI0417829A/pt not_active IP Right Cessation
- 2004-12-20 RU RU2006126062/14A patent/RU2367423C2/ru not_active IP Right Cessation
- 2004-12-20 AT AT04815013T patent/ATE515261T1/de not_active IP Right Cessation
- 2004-12-20 AR ARP040104812A patent/AR047779A1/es unknown
- 2004-12-20 AU AU2004308934A patent/AU2004308934B2/en not_active Ceased
- 2004-12-20 CN CN2010102231017A patent/CN101897970A/zh active Pending
- 2004-12-20 KR KR1020067013737A patent/KR101329369B1/ko not_active IP Right Cessation
- 2004-12-20 MY MYPI20045235A patent/MY143799A/en unknown
- 2004-12-20 WO PCT/US2004/042884 patent/WO2005063226A1/fr active Application Filing
-
2006
- 2006-06-12 IL IL176259A patent/IL176259A/en not_active IP Right Cessation
-
2007
- 2007-02-28 HK HK07102258.6A patent/HK1099507A1/xx not_active IP Right Cessation
-
2008
- 2008-10-28 US US12/259,721 patent/US8188151B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL176259A (en) | 2016-02-29 |
EP1696897A4 (fr) | 2008-12-10 |
JP2007514771A (ja) | 2007-06-07 |
AR047779A1 (es) | 2006-02-22 |
ATE515261T1 (de) | 2011-07-15 |
AU2004308934B2 (en) | 2010-04-01 |
EP1696897A1 (fr) | 2006-09-06 |
SG149814A1 (en) | 2009-02-27 |
MY143799A (en) | 2011-07-15 |
MXPA06007100A (es) | 2007-01-19 |
RU2367423C2 (ru) | 2009-09-20 |
CA2549717C (fr) | 2012-11-13 |
KR101329369B1 (ko) | 2013-11-14 |
WO2005063226A1 (fr) | 2005-07-14 |
KR20070004569A (ko) | 2007-01-09 |
TWI350751B (en) | 2011-10-21 |
US8188151B2 (en) | 2012-05-29 |
US7442720B2 (en) | 2008-10-28 |
JP4845740B2 (ja) | 2011-12-28 |
US20090048154A1 (en) | 2009-02-19 |
TW200524583A (en) | 2005-08-01 |
US20050137125A1 (en) | 2005-06-23 |
EP1696897B1 (fr) | 2011-07-06 |
RU2006126062A (ru) | 2008-01-27 |
IL176259A0 (en) | 2006-10-05 |
CA2549717A1 (fr) | 2005-07-14 |
CN101897970A (zh) | 2010-12-01 |
AU2004308934A1 (en) | 2005-07-14 |
BRPI0417829A (pt) | 2007-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1099507A1 (en) | Compositions for treating diabetes | |
IL185761A0 (en) | Pharmaceutical compositions for treating diabetes | |
GB0305941D0 (en) | Composition | |
EP1493437A4 (fr) | Compositions contre le diabete | |
GB0302738D0 (en) | Composition | |
GB0324918D0 (en) | Composition | |
GB0307695D0 (en) | Compounds,compositions and processes | |
GB0324897D0 (en) | Composition | |
HK1087034A1 (en) | Actacid composition | |
GB0322033D0 (en) | Composition | |
GB0318824D0 (en) | Novel composition | |
GB0305790D0 (en) | Novel Composition | |
MY145151A (en) | Composition | |
GB0313246D0 (en) | Bleaching composition | |
GB0309317D0 (en) | Composition | |
EP1660007A4 (fr) | Compositions pour le traitement et la prevention du diabete | |
GB0404470D0 (en) | Composition | |
GB0306312D0 (en) | Composition | |
GB0301869D0 (en) | Composition | |
GB0326815D0 (en) | Composition | |
IL155550A0 (en) | Plant derived composition for treating diabetes | |
GB0313249D0 (en) | Bleaching composition | |
HU0301894D0 (en) | Wood-protecting composition for general purpose | |
GB0323207D0 (en) | Composition I | |
GB0303643D0 (en) | Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171220 |